TrialJournal for immunotherapy of cancer2024

Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells.

Maxim Yankelevich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.